Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antinavikiniai vaistai - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - Šizofrenija - psicholeptikai - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - plaučių liga, lėtinė obstrukcinė - vaistai nuo obstrukcinių kvėpavimo takų ligų, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glikogeno kaupimo ligos ii tipas - kiti virškinimo trakto ir metabolizmo produktus, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresantai - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glikogeno kaupimo ligos ii tipas - kiti virškinimo trakto ir metabolizmo produktus, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabriko liga - kiti virškinimo trakto ir metabolizmo produktus, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

amicus therapeutics europe limited - miglustatas - glikogeno kaupimo ligos ii tipas - kiti virškinimo trakto ir metabolizmo produktai - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - krūties navikai - endokrininė terapija - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.